GlobeImmune, Inc.

GBIM

US37957B1008

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:13:20 15/03/2024 am IST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

2022	Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital announced an offer to acquire 12.2% stake in GlobeImmune, Inc. for $7,000.	CI
2017	NantCell, Inc. Exercises Option for Licensing Agreement with GlobeImmune, Inc. for GI-6100	CI

GlobeImmune Explores Strategic Alternatives

August 13, 2015 at 09:30 am IST

GlobeImmune Inc. (NasdaqCM:GBIM) retained financial advisor Cantor Fitzgerald, L.P. to assist in "evaluating strategic alternatives intended to maximize shareholder value."

Latest news about GlobeImmune, Inc.

Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital announced an offer to acquire 12.2% stake in GlobeImmune, Inc. for $7,000.	06/22/06	CI
NantCell, Inc. Exercises Option for Licensing Agreement with GlobeImmune, Inc. for GI-6100	31/17/31	CI
NantCell, Inc. Enters into Licensing Agreement with GlobeImmune, Inc. for GI-4000	31/17/31	CI
NantCell, Inc. Enters into Licensing Agreement with GlobeImmune, Inc. for GI-6207 and GI-6301	31/17/31	CI
GlobeImmune, Inc. announced a financing transaction	20/17/20	CI
Gilead Sciences, Inc. Terminates the Collaboration and License Agreement with GlobeImmune	18/16/18	CI
GlobeImmune Inc. Announces Management and Board Changes	18/16/18	CI
GlobeImmune Inc.(OTCPK:GBIM) dropped from S&P TMI Index	25/16/25	CI
GlobeImmune Inc.(OTCPK:GBIM) dropped from NASDAQ Composite Index	24/16/24	CI
Globeimmune, Inc Announces Financial Results for the First Quarter Ended March 31, 2016	12/16/12	CI
GlobeImmune Seeks Alternatives	12/16/12	CI
GlobeImmune Inc.(NasdaqCM:GBIM) dropped from CRSP US Total Market Index	21/16/21	CI
GlobeImmune Inc. Reports Earnings Results for the Year Ended December 31, 2015; Provides Update on Clinical Programs	16/16/16	CI
GlobeImmune Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	13/15/13	CI
GlobeImmune Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2015	14/15/14	CI
GlobeImmune Weighing A Potential Sale	14/15/14	CI
GlobeImmune Explores Strategic Alternatives	13/15/13	CI
Globeimmune, Inc. Enters into License Agreement with Celgene Corporation	04/15/04	CI
Kirk Christoffersen to Leave GlobeImmune Inc. as Vice President, Corporate Development, Effective Aug. 3, 2015	18/15/18	CI
GlobeImmune to Lay Off Majority of its Workforce	11/15/11	CI
GlobeImmune Explores Strategic Options	10/15/10	CI
GlobeImmune, Inc. Announces Line Results from GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients	27/15/27	CI
GlobeImmune Inc. Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute	22/15/22	CI
Globeimmune, Inc. Provides Update on Business and Clinical Programs; Reports Earnings Results for the Year Ended December 31, 2014	17/15/17	CI
3,628,245 Common Stock of GlobeImmune, Inc. are subject to a Lock-Up Agreement Ending on 27-DEC-2014.	27/14/27	CI

GlobeImmune Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Companyâs Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. It has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Company's oncology product candidates include GI-6301, GI-6207 and GI-4000. The Company's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GLOBEIMMUNE, INC.	-.--%	5
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	114B
REGENERON PHARMACEUTICALS, INC.	+11.60%	105B
BIONTECH SE	-4.68%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-17.47%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.75B
SAREPTA THERAPEUTICS, INC.	+34.58%	11.76B

Bio Therapeutic Drugs

GlobeImmune, Inc.

Equities

GBIM

US37957B1008

Biotechnology & Medical Research

GlobeImmune Explores Strategic Alternatives

Latest news about GlobeImmune, Inc.

Chart GlobeImmune, Inc.

Company Profile

Sector Bio Therapeutic Drugs